Neuberger Berman Group
ANTH

Neuberger Berman Group’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Neuberger Berman Group’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-34,110
Closed -$56K – 1805
2017
Q4 		$56K Buy
34,110
+125
+0.4% +$215 ﹤0.01% 1741
2017
Q3 		$49K Buy
+33,985
New +$48.3K ﹤0.01% 1588

Other funds holding ANTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Neuberger Berman Group's ANTH Position: Q1 2018 in Review

Neuberger Berman Group sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2018, closing a stake of 34,110 shares — an estimated $56K sold.

Neuberger Berman Group first reported a position in ANTH in Q3 2017 and held it in 2 quarters. The position peaked at $56K in Q4 2017. 28 funds tracked by Wall St. Rank hold ANTH as of Q1 2018.

  • Neuberger Berman Group reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 34,110 Anthera Pharmaceuticals, Inc. shares in Q1 2018, an estimated $56K.
  • Neuberger Berman Group first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Neuberger Berman Group's Anthera Pharmaceuticals, Inc. position peaked at $56K in Q4 2017.
  • 28 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2018.

Based on Neuberger Berman Group's 13F filing for Q1 2018, filed 8 May 2018.